Effect of Henagliflozein on Hepatic Fat Content in Patients With T2DM and NAFLD
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 100 participants.
Also called NCT06449833
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 100 participants
- Sponsor
- Registry
-
NCT06449833
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Recruiting
Technical summary
Registry record NCT06449833. Randomized; double masking; primary purpose treatment. Start 2024-06 (anticipated); primary completion 2026-11 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effect of Henagliflozein on Hepatic Fat Content in Patients With T2DM and NAFLD
- Acronym
- HHTN
- Condition
- Type2 Diabetes Mellitus
- Condition
- Nonalcoholic Fatty Liver Disease
- Intervention (Drug)
- Henagliflozein and Metformin
- Intervention (Drug)
- Linagliptin and Metformin
- Lead sponsor
- Zhujiang Hospital
Record details
- Record id
cardio:ct-nct06449833- Content hash
e49e365028bc595529f82f8ec8ddff2fa24d2f322c6d7128ab9a5c8ebe5f3aae